公开(公告)号：US20240358824A1

公开(公告)日：2024-10-31

申请号：US18194864

申请日：2023-04-03

申请人： PULMOTECT, INC. ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  BAYLOR COLLEGE OF MEDICINE

发明人： BURTON DICKEY ,  SCOTT EVANS ,  BRIAN GILBERT ,  DIANE MARKESICH ,  MICHAEL TUVIM ,  BRENTON SCOTT

IPC分类号： A61K39/39 ,  A61K9/00 ,  A61K31/215 ,  A61K31/24 ,  A61K31/7056 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K39/00 ,  A61K45/06

CPC分类号： A61K39/39 ,  A61K9/0078 ,  A61K31/215 ,  A61K31/24 ,  A61K31/7056 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K45/06 ,  A61K2039/55561 ,  Y02A50/30

摘要： Embodiments are directed to compositions and methods for treating viral infections.

公开(公告)号：US20240342290A1

公开(公告)日：2024-10-17

申请号：US18674657

申请日：2024-05-24

申请人： OneSkin, Inc. ,  UNIVERSIDADE CATÓLICA DE BRASÍLIA ,  UNIÃO BRASILEIRA DE EDUCAÇÃO CATÓLICA, BRASÍLIA

发明人： Alessandra ZONARI ,  Carolina Reis de OLIVEIRA ,  Edgar Andres OCHOA ,  Juliana Lott de CARVALHO ,  Lear BRACE ,  Mariana BORONI ,  Mylieneth GUIANG ,  Octávio FRANCO ,  William Farias PORTO ,  Thuany de Alencar e SILVA

IPC分类号： A61K47/42 ,  A61K9/06 ,  A61K38/07 ,  A61K38/08 ,  A61K38/16 ,  A61K47/46 ,  A61K47/55 ,  C07K7/06

CPC分类号： A61K47/42 ,  A61K9/06 ,  A61K38/07 ,  A61K38/08 ,  A61K38/16 ,  A61K47/46 ,  A61K47/551 ,  C07K7/06

摘要： Polypeptides which can provide a senotherapeutic effect are provided herein. The polypeptides can be formulated for topical application and can be applied topically to a subject to provide a senotherapeutic effect in the subject or in the cells of the subject.

公开(公告)号：US20240342238A1

公开(公告)日：2024-10-17

申请号：US18574665

申请日：2022-06-28

申请人： Korea University Research and Business Foundation

发明人： Min Jeong SHIN ,  In Hyeok JEONG

IPC分类号： A61K38/08 ,  A61K38/06 ,  A61K38/10 ,  A61K38/17 ,  A61P3/04 ,  A61P21/00

CPC分类号： A61K38/08 ,  A61K38/06 ,  A61K38/10 ,  A61K38/1709 ,  A61P3/04 ,  A61P21/00

摘要： The present invention relates to a peptide having obesity and muscle loss inhibitory activities, and a use thereof. The peptide has excellent effects on suppressing appetite, promoting energy metabolism, inhibiting fat accumulation, and promoting lipolysis, and inhibits muscle atrophy while promoting muscle synthesis, such that the peptide can be effectively used for the prevention or treatment of obesity and sarcopenia.

公开(公告)号：US20240335499A1

公开(公告)日：2024-10-10

申请号：US18574406

申请日：2022-06-28

申请人： MEDI&GENE INC.

发明人： Min Jeong Shin ,  In Hyeok Jeong

IPC分类号： A61K38/06 ,  A61K38/08 ,  A61K38/10 ,  A61P3/06 ,  A61P3/10 ,  A61P13/12

CPC分类号： A61K38/06 ,  A61K38/08 ,  A61K38/10 ,  A61P3/06 ,  A61P3/10 ,  A61P13/12

摘要： The present invention relates to a novel peptide having an antidiabetic activity. The peptide improves sugar metabolism and insulin resistance, inhibits amyotrophy while increasing muscle mass, and protects renal functions, and thus may be used for treating and relieving diabetes and diabetic complications.

公开(公告)号：US20240316141A1

公开(公告)日：2024-09-26

申请号：US18578153

申请日：2022-07-15

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Laurent BEKALE ,  Peter Luke SANTA MARIA ,  Annelise E. BARRON ,  Jennifer Sue LIN

IPC分类号： A61K38/08 ,  A61K31/17 ,  A61K31/5383 ,  A61K38/10 ,  A61P31/04

CPC分类号： A61K38/08 ,  A61K31/17 ,  A61K31/5383 ,  A61K38/10 ,  A61P31/04

摘要： Methods for treating bacterial infections using combination therapy with thiourea or a derivative thereof and an antimicrobial peptoid are disclosed. Treatment may further comprise administration of an antibiotic. The disclosed methods may be used for the treatment of acute and chronic bacterial infections. The antimicrobial peptoid may be a self-assembly peptoid.

公开(公告)号：US20240307482A1

公开(公告)日：2024-09-19

申请号：US18735024

申请日：2024-06-05

申请人： Illustris Pharmaceuticals, Inc.

发明人： Siak Khim TAN

IPC分类号： A61K38/08 ,  A61K9/00 ,  A61K9/06 ,  A61K31/728 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61K38/39

CPC分类号： A61K38/08 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/728 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07 ,  A61K38/39

摘要： Compositions for dermal delivery of a topical solution and methods for using such compositions are described herein. The compositions may contain extracellular matrix components and therapeutic peptides.

公开(公告)号：US20240301427A1

公开(公告)日：2024-09-12

申请号：US18670885

申请日：2024-05-22

申请人： Oklahoma Medical Research Foundation ,  The Board of Regents of Universtity of Oklahoma

发明人： Yuji Kondo ,  Jianxin Fu ,  Hua Wang ,  Klaas Wierenga ,  Patrick M. Gaffney ,  Lijun Xia

IPC分类号： C12N15/113 ,  A61K31/155 ,  A61K31/18 ,  A61K31/192 ,  A61K31/26 ,  A61K31/4045 ,  A61K31/436 ,  A61K31/575 ,  A61K38/05 ,  A61K38/07 ,  A61K38/08 ,  A61K45/06 ,  A61P19/08 ,  C12N15/64

CPC分类号： C12N15/1137 ,  A61K31/155 ,  A61K31/18 ,  A61K31/192 ,  A61K31/26 ,  A61K31/4045 ,  A61K31/436 ,  A61K31/575 ,  A61K38/05 ,  A61K38/07 ,  A61K38/08 ,  A61P19/08 ,  C12N15/64 ,  A61K45/06

摘要： The present invention includes a method of treating a bone disease caused by a intracellular protein trafficking defect comprising: identifying a subject having the bone disease caused by the intracellular protein trafficking defect in a membrane bound transcription factor peptidase, site 1 (MBTPS1) gene; and providing the subject with an effective amount of a composition that bypasses or corrects a defect in MBTPS1 gene expression, gene splicing, or corrects protein trafficking defects in the endoplasmic reticulum and to the lysosome.

公开(公告)号：US20240294602A1

公开(公告)日：2024-09-05

申请号：US18647837

申请日：2024-04-26

申请人： Immatics Biotechnologies GmbH

发明人： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC分类号： C07K14/74 ,  A01N37/46 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569

CPC分类号： C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/04 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

摘要： A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20240277797A1

公开(公告)日：2024-08-22

申请号：US18650002

申请日：2024-04-29

申请人： Suzhou Mingren Pharmaceutical Biotechnology Co., Ltd.

发明人： Jianwei ZHOU ,  Zhan XIE

IPC分类号： A61K38/08 ,  A61P9/10 ,  A61P27/02

CPC分类号： A61K38/08 ,  A61P9/10 ,  A61P27/02

摘要： A method for treating or preventing a neovascular eye disease including: administering a patient in need thereof a pharmaceutical composition including a polypeptide, the peptide having an amino acid sequence I or II; I: FPGSDRF (SEQ ID NO: 1)-Z; II: X-FPGSDRF (SEQ ID NO: 1)-Z; S represents phosphorylated serine; X and Z independently represents an amino acid or an amino acid sequence; X is selected from F, (R)9 (SEQ ID NO: 2), (R)9-F (SEQ ID NO: 3), 6-aminohexanoic acid, 6-aminohexanoic acid-F, 6-aminohexanoic acid-(R)9 (SEQ ID NO: 2), 6-aminohexanoic acid-(R)9-F (SEQ ID NO: 3); and Z is selected from (G)n-RGD or A-(G)n-RGD (SEQ ID NO: 4), where n is an integer greater than or equal to 0, in the range of 0-10.

公开(公告)号：US20240269226A1

公开(公告)日：2024-08-15

申请号：US18434973

申请日：2024-02-07

申请人： Hallstat Capital LLC

发明人： Bruice T. Huici

IPC分类号： A61K38/08 ,  A61K31/00

CPC分类号： A61K38/08 ,  A61K31/658

摘要： The invention describes novel methods of treating patients with a combination of a Semax compound and cannabinoid and compositions containing the same. For example, in an aspect the combination can be used to reduce the likelihood of cell death after ischemic stroke and aid in cell repair in damaged cells effected by ischemic stroke.